Cargando…

Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway

OBJECTIVES: Despite advances in the development of novel targeted therapies, the need for B-ALL alternative treatments has not been met. Anlotinib could blunt the proangiogenic activity of VEGFR, PDGFR, and FGFR, and has shown strong antitumor activities across multiple tumors. However, anlotinib cy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Qiuling, Lai, Qian, Jiang, Yuelong, Yao, jingwei, Chen, Qinwei, Zhang, Li, Wang, Caiyan, Zhou, Yong, Deng, Manman, Xu, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418595/ https://www.ncbi.nlm.nih.gov/pubmed/35985203 http://dx.doi.org/10.1016/j.tranon.2022.101516

Ejemplares similares

Non-Thermal Plasma Induces Antileukemic Effect Through mTOR Ubiquitination
por: Kim, Sun-Yong, et al.
Publicado: (2020)

Targeting lactate dehydrogenase A (LDHA) exerts antileukemic effects on T‐cell acute lymphoblastic leukemia
por: Yu, Haizhi, et al.
Publicado: (2020)

Azelaic Acid Exerts Antileukemic Activity in Acute Myeloid Leukemia
por: Pan, Yunbao, et al.
Publicado: (2017)

Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019)

Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia
por: Bridges, Cory Seth, et al.
Publicado: (2022)

Clofarabine exerts antileukemic activity against cytarabine‐resistant B‐cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression
por: Huang, Meixian, et al.
Publicado: (2018)

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
por: Zhu, Zhongling, et al.
Publicado: (2021)

Analysis of Plant–Plant Interactions Reveals the Presence of Potent Antileukemic Compounds
por: Mery, David E., et al.
Publicado: (2022)

Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells
por: Jiang, Yuelong, et al.
Publicado: (2022)

Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia
por: Ramsey, Laura B., et al.
Publicado: (2015)

The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
por: Kuwatsuka, Y, et al.
Publicado: (2011)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

Therapeutic Interaction of Apatinib and Chidamide in T-cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis
por: Zhong, Mengya, et al.
Publicado: (2021)

Oncogene-independent resistance in Philadelphia chromosome - positive (Ph(+)) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2016)

Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements
por: Roolf, C., et al.
Publicado: (2018)

A Novel 2-Carbon-Linked Dimeric Artemisinin With Potent Antileukemic Activity and Favorable Pharmacology
por: Kagan, Amanda B., et al.
Publicado: (2022)

Baicalein Triggers Mitochondria-Mediated Apoptosis and Enhances the Antileukemic Effect of Vincristine in Childhood Acute Lymphoblastic Leukemia CCRF-CEM Cells
por: Chen, Yun-Ju, et al.
Publicado: (2013)

Orexin-A exerts neuroprotective effect in experimental intracerebral hemorrhage by suppressing autophagy via OXR1-mediated ERK/mTOR signaling pathway
por: Zhang, Dexin, et al.
Publicado: (2022)

Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs
por: Fox, Jennifer M., et al.
Publicado: (2016)

Inhibition of the mTOR Pathway Exerts Cardioprotective Effects Partly through Autophagy in CLP Rats
por: Han, Wen, et al.
Publicado: (2018)

Matrine Exerts Antidepressant-Like Effects on Mice: Role of the Hippocampal PI3K/Akt/mTOR Signaling
por: Wu, Zhonghua, et al.
Publicado: (2018)

5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia
por: Meffre, Julie, et al.
Publicado: (2012)

How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?
por: Pinchinat, Ashley, et al.
Publicado: (2022)

Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia
por: Buono, Roberta, et al.
Publicado: (2023)

Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo
por: Ji, Yurou, et al.
Publicado: (2022)

Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels
por: Pillozzi, S, et al.
Publicado: (2016)

Antileukemic activity of novel adenosine derivatives
por: Poczta, Anastazja, et al.
Publicado: (2019)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis
por: Reddy, Padmalatha S, et al.
Publicado: (2008)

Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization
por: Kuger, Sebastian, et al.
Publicado: (2015)

mTOR Inhibition by Everolimus in Childhood Acute Lymphoblastic Leukemia Induces Caspase-Independent Cell Death
por: Baraz, Rana, et al.
Publicado: (2014)

Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
por: Shi, Pei-Jie, et al.
Publicado: (2016)

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia
por: Wong, Jacky, et al.
Publicado: (2014)

Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia
por: Chang, Yoon Soo, et al.
Publicado: (2023)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Sulfonoquinovosyl diacylglyceride selectively targets acute lymphoblastic leukemia cells and exerts potent anti-leukemic effects in vivo
por: Jain, Chetan Kumar, et al.
Publicado: (2015)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
por: Shi, Mingyue, et al.
Publicado: (2019)

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
por: Gotesman, Moran, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e4q3rvtpg4fmmtho9t8b0i0rc7